Emcure ERIBILIN is one of the world first generic version of Eisai Pharmaceutical’s Halaven (Eribulin) that is used for the treatment of metastatic breast cancer.
ERIBILIN has been developed by Emcure Pharmaceuticals and provides the same quality and efficacy as one of the original brand.
Emcure ERIBILIN (Generic Eribulin)
Emcure Pharmaceuticals is one of the most promising and innovative pharmaceutical company in India which has announced the launch of the world’s first generic version of Japanese drugmaker Eisai pharmaceuticals Halaven (Eribulin) for the treatment of metastatic breast cancer.
Emcure will be going to the manufacturer and marketing their breast cancer drug under the brand name ‘ERIBILIN with the aim of providing with a cost-effective and high-quality treatment option to metastatic breast cancer patients in India.
Emcure will also market it at a price range which will also be around 40% less than the innovator/international brand that is also providing hope to the wide range of the patients of metastatic breast cancer in India.
Emcure Pharmaceuticals is also one of the leading integrated global pharmaceutical companies in India. Generic Eribulin is also a very significant achievement of the Emcure’s R&D efforts. This also brings hope to the millions of breast cancer patients in India.
Generic Eribulin for triple negative metastatic breast cancer
ERIBILIN (Generic Eribulin) has also emerged as an effective, easy and least toxic to administer second-line treatment for the relapsing patients, diagnosed with the triple negative breast cancer.
Breast cancer in India
According to the report from the Indian Council of Medical Research and Population revealed. As of now, breast cancer is one of the most spreading cancer which is also affecting several women in India.
Some of the various reports suggest that more than 23% of breast cancers are triple negative breast cancer.
There are more than 1.6 lakh breasts cancer cases which is available in India. Many people not able to get drugs due to problems such as limited access and affordability.
Moreover, the world-class breast cancer treatment is available in India; the majority of the patients are unable to access it due to the lack of quality infrastructure which is of high quality, financial resources, and skills. Currently, available treatment for triple negative breast cancer in India is out of reach of most patients due to its high cost.
After the Emcure generic Eribulin medicine comes into the market, many patients can also be able to take quality treatment at a very low cost.
Eribulin generic cost price in India
Eribulin generic drug cost approximately 40% less than the innovator/international brand in India.
The Emcure pharmaceuticals India company is offering ERIBILIN (Generic Eribulin) at INR 19,000 per vial, One cycle needs around four vials and a full treatment of four cycles would cost roughly INR 3 lakh, while Eisai sells Halaven at INR 31,880 per vial, charging roughly about INR 5 lakh.
Eribulin figured in the list of 42 cancer drugs, whose trade margins were capped at 30% by NPPA in February 2019.
Please contact me for questions related to generic Eribulin. I’m here to help you. You can contact me directly on WhatsApp + 918851226314 or send me an e-mail firstname.lastname@example.org
Disclaimer: the prices can vary on time to time. We are not claiming that the above prices are fully accurate.